Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
1(13%)
Results Posted
50%(1 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_2
2
25%
Ph not_applicable
3
38%
Ph phase_3
2
25%
Ph phase_4
1
13%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
2(25.0%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
3(37.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)
Other(3)

Detailed Status

unknown3
Completed2
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (25.0%)
Phase 32 (25.0%)
Phase 41 (12.5%)
N/A3 (37.5%)

Trials by Status

unknown338%
completed225%
active_not_recruiting113%
terminated225%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingnot_applicable

An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer

NCT04871139
terminatedphase_2

Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers

NCT03109847
terminatedphase_3

Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules

NCT05142904
unknownphase_2

The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.

NCT04447183
completedphase_4

LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidism

NCT05512715
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04871139Not Applicable

An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer

Active Not Recruiting
NCT03109847Phase 2

Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers

Terminated
NCT05142904Phase 3

Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules

Terminated
NCT04447183Phase 2

The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.

Unknown
NCT05512715Phase 4

LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidism

Completed
NCT04396158Not Applicable

Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer

Unknown
NCT00115895Phase 3

The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy

Unknown
NCT00509483Not Applicable

Three-Year Follow-up of Radioiodine Therapy for Goitre

Completed

All 8 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
8